Parenteral delivery of long-acting glucagon-like peptide-1 (GLP-1) mimetics has received much attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments may provide a more physiological regulation of blood glucose. The present study assessed the effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell implantation was well tolerated and had no appreciable metabolic effects in normal mice. However, transplantation significantly (Po0.001) countered excessive food and fluid intake in diabetic mice and maintained normal body weight. Circulating glucose (Po0.01) and glucagon (Po0.05) were significantly reduced and plasma insulin and GLP-1 dramatically increased. This was associated with significantly (Po0.01) improved glucose tolerance in diabetic mice. Histological examination of the pancreata of these mice revealed elevations (Po0.001) in islet and b-cell area, with reduced (Po0.001) a-cell area. Increased b-cell mass reflected the enhanced proliferation relative to apoptosis. These studies emphasize the potential of chronic GLP-1 delivery by cell therapy as a potential therapeutic option for diabetes.
INTRODUCTION
Diabetes mellitus (DM) is a degenerative metabolic disease caused by the absence (type 1), or insufficient production (type 2), of insulin from pancreatic b-cells. Insulin therapy is the first line of treatment for type 1 DM. 1 In addition, the early use of insulin to improve metabolic regulation in poorly controlled type 2 DM is increasingly common. 2 Notwithstanding this, exogenous insulin administration is associated with serious adverse effects including weight gain, possible increased risk of colorectal cancer and lifethreatening hypoglycemia. 2 In patients with poor management and brittle diabetes, quality of life can be greatly improved by islet transplantation. 3, 4 However, major limitations of islet transplantation include availability of human pancreata, chronic immunosuppression, immune-mediated apoptosis, a lack of vascularization and ultimately loss of function. 4, 5 Thus, newer avenues to adequately maintain blood glucose homeostasis in poorly controlled diabetic patients are required to avoid the plethora of associated progressive disease complications.
In this respect, the incretin hormone glucagon-like peptide-1 (GLP-1) has generated significant therapeutic interest for diabetes owing to its pleiotropic beneficial effects, including weight loss, lowering of blood glucose, stimulation of glucose-induced insulin secretion, inhibition of gastric emptying and glucagon secretion and promotion of pancreatic b-cell growth and survival. 6 As such, long-acting enzyme-resistant GLP-1 mimetics are now routinely used in the diabetic clinic, and are indicated for type 2 DM when glycemic control is inadequate with metformin and sulfonylurea treatment. 7 Moreover, in patients already receiving insulin therapy, the addition of GLP-1 often facilitates a reduction in insulin dose. 7 Further to this, GLP-1 has postulated important beneficial effects in type 1 DM patients with or without residual bcell function. 8 In agreement, increased b-cell proliferation and mass has been demonstrated in type 1 diabetic NOD mice treated with long-acting GLP-1 mimetics in combination with gastrin, 9 although evidence is still lacking in humans.
Despite the attractiveness of longer-acting GLP-1 mimetics, timing of injections remains an issue with some agents being given one or two times per day, weekly or even potentially monthly. 10 As such, in situ production of GLP-1 by cellular delivery could assure more even and possibly physiological levels while eliminating the need for injection. 11 However, the effectiveness of this strategy is unknown as is the need to limit GLP-1 degradation by interfering with the normal dipeptidyl peptidase IV-mediated mechanisms involved in peptide degradation. 12 This may be particularly relevant given the idea that the degradation fragment, GLP-1(9-36), may also mediate biological actions. 13 The GLUTag cell line, generated using a colonic tumor of a transgenic mouse expressing the SV40 large T antigen, is a well-characterized GLP-1-secreting cell line.
14 Interestingly, a transfected insulin-secreting version of the same cell line has previously been implanted intraperitoneally in diabetic mice with some minor beneficial effects. 15 Therefore, to evaluate the potential of cell therapy of GLP-1 for diabetes, we have investigated the effects of chronic GLP-1 delivery using subscapular implantation of GLUTag cells in normoglycemic and streptozotocin-induced diabetic mice. We assessed effects on GLUTag cell aggregate growth and GLP-1 expression following implantation, as well as biological actions on food and fluid intake, body weight, non-fasting glucose, insulin, glucagon and GLP-1 concentrations, glucose homeostasis and intestinal and pancreatic morphology. The results provide experimental evidence that GLP-1 delivery by cell therapy may provide a useful approach for the treatment of diabetes.
RESULTS
Size, morphology and GLP-1 expression of implanted GLUTag cell masses GLUTag cells formed cellular aggregates after 30 days of transplantation, suggesting good tolerance in both normal and diabetic mice (Figure 1 ). These weighed between 0.35 and 0.91 g and 0.21 and 0.81 g with cell mass sizes between 11 Â 12 and 21 Â 18 mm 2 and 9 Â 8 and 21 Â 19 mm 2 in normoglycemic and diabetic mice, respectively ( Table 1 ). The cell aggregates were encapsulated, well vascularized and without any obvious areas of central necrosis (Figure 1 ). Cell masses expressed uniform dark stained GLP-1 immunoreactivity as assessed by immunohistochemistry (Figure 1 ). GLP-1 content of cell masses was 154.66 pg mg À 1 protein.
Effects on food and water intake, body weight and metabolic control Food intake was marginally decreased at some observations points in normal mice following chronic GLP-1 delivery by cell therapy when compared with controls ( Figure 2a ). However, water intake, body weight and circulating glucose and insulin were not significantly affected in these mice (Figures 2c, e and 3a, c). In streptozotocin-induced diabetic mice, subscapular GLUTag cell implantation was associated with a significantly (Po0.001) decreased food and fluid intakes from day 24 post-transplantation onwards (Figures 2b and d) . Body weights of diabetic mice receiving chronic GLP-1 delivery were also maintained at near normal levels and were significantly (Po0.001) greater than untreated diabetic controls, which exhibited progressive weight loss despite insulin therapy (Figure 2f ). Further to this, circulating glucose was significantly (Po0.01) decreased in transplanted mice from day 9 post-implantation onwards ( Figure 3b ) and plasma insulin was substantially raised at 1.9 ± 0.7 ng ml À 1 on day 30, compared with undetectable levels of insulin in diabetic controls (Figure 3d ). At this time, plasma GLP-1 levels were significantly elevated (Po0.05) and glucagon levels reduced (Po0.05) in GLUTag cell-implanted mice (Figures 3e and f) . Finally, following exogenous glucose administration, blood glucose levels of GLUTag cell-transplanted mice were significantly (Po0.05 to Po0.01) lower than diabetic controls at all time points examined (Figure 4a ). This improvement of glucose tolerance was corroborated by a significantly (Po0.01) decreased 0-90 min area under the curve value in GLUTag cell-implanted mice (Figure 4b ).
Effects on intestinal GLP-1 expression and pancreatic morphology No obvious changes in intestinal morphology were noted in any of the groups (Figures 5a and d) 
DISCUSSION
We utilized cell therapy with GLP-1-secreting GLUTag cells to evaluate the consequences of chronic GLP-1 delivery in normal and streptozotocin-induced diabetic severe combined immunodeficient (SCID) mice. There were no adverse or appreciable metabolic effects of GLUTag cell transplantation in normal mice barring minor inhibition of food intake, which did not translate to changes in body weight. However, in harmony with the important anti-diabetic action of GLP-1, 6 GLUTag cellimplanted diabetic mice displayed significantly increased circulating insulin, reduced glucose levels and markedly enhanced glucose tolerance compared with untreated diabetic controls by day 30. This was associated with development of encapsulated and well-vascularized GLP-1-containing cell masses, which were confined to the transplantation site, with no obvious signs of metastasis observed following animal kill. However, it should be noted that implantation of GLUTag cells into the spleen of mice has been shown to lead to the development of intrahepatic tumors. 16 In addition, lymphocyte infiltration was not assessed in the current study, which could be important, particularly in mice without compromised immune responses. In the current study, implanted mice displayed substantially increased circulating GLP-1 levels, consistent with the cellular implants exhibiting secretory function. Observation of these metabolic effects implies that the need to interfere with normal dipeptidyl peptidase IV-mediated mechanisms involved in incretin degradation is not a requirement for therapeutic effectiveness of GLP-1 cell therapy approaches. Although unproven, this may be beneficial as the major degradation fragment of native GLP-1, Po0.01 and *** Po0.001 compared with respective controls.
Chronic GLP-1 cell therapy S Vasu et al GLP-1(9-36), has been reported to mediate independent biological actions. 13 Chronic GLP-1 delivery in diabetic mice was associated with substantial reductions in the characteristic hyperphagia and polydipsia induced by streptozotocin treatment. Although it is well acknowledged that GLP-1 reduces energy intake, 6 changes in fluid intake most likely reflect substantial reductions of blood glucose. The anorectic hormone peptide YY (PYY), which is converted to active PYY(3-39) by dipeptidyl peptidase IV, is also secreted from L-cells and may possibly act additively with GLP-1 to supress appetite. 17 However, GLUTag cells do not express mRNA for PYY, 18 making it highly unlikely that secretion of PYY contributes to the results of the present study. However, these cells may secrete oxyntomodulin and glicentin, 14 which, although lacking the biological activity of GLP-1, might feasibly contribute to the current phenotype. Nevertheless, GLUTag cell therapy had encouraging effects on body weight control in diabetic mice, with streptozotocin-treated animals maintaining near normal body weights throughout the entire study period. As with other parameters, beneficial effects not only persisted but also actually continued to improve after withdrawal of insulin therapy, suggesting that the cellular implant facilitated sustained insulin independence. In this regard, it would be interesting to examine if GLUTag cell-transplanted mice could maintain normoglycaemia with reduced, or even without, insulin therapy. Although the usefulness of GLP-1 mimetics in type 2 DM is well recognized, 6 relatively little attention has been given previously to the beneficial effects of GLP-1 in situations of b-cell failure and insulin deficiency. Consistent with the present results, GLP-1 protected against virally induced diabetes, b-cell destruction and GLP-1 gene constructs reversed diabetes in type 1 diabetic NOD mice. 19, 20 Moreover, fasting blood glucose levels of type 1 DM patients were lowered by GLP-1 independent of residual b-cell function, 8 highlighting the clinical applicability of these findings. The dose of streptozotocin employed in the present study resulted in severe hyperglycemia (glucose430 mM), vanishingly low insulin levels, reduced numbers of small and irregularly sized islets with few surviving b-cells and increased numbers of glucagon-positive a-cells. However, GLP-1 cell therapy caused substantial increases in islet area in diabetic but not normoglycaemic mice. Remarkably, previous studies in normoglycaemic animals reported increased circulating glucagon and a paradoxical reduction in the number and size of islets following transplantation of the tumors from which GLUTag cells were derived. 21 The reason for this is unclear, but may reflect subsequent cloning or secretion of glucagon rather than GLP-1. However, more notably we observed a marked expansion of b-cell mass in streptozotocintreated mice associated with increased numbers of medium sized islets and increased proliferation relative to apoptosis of new insulin-containing cells, as revealed by Ki-67 and TUNEL staining, respectively. Islet a-cell mass was decreased, but unlike original transplantation studies 21 this translated to significantly lower circulating glucagon concentrations. Thus, the improvement of metabolic status in cell-implanted diabetic mice in the current study appears to be due to the dual action of biologically active GLP-1 to stimulate insulin release and inhibit glucagon secretion. 6 However, the effect also clearly extended to corresponding changes in the populations of both major islet cell types. The effect on b-cells is consistent with the view of GLP-1 as a proliferative agent for b-cells, 2 although anti-apoptosis effects of GLP-1 relative to normal islets were not evident in the present study. The importance of the proliferative effects of GLP-1 corresponds to other studies, which have shown positive effects on b-cells from diabetic mice, aging and pancreatomized rats, rat b-cells exposed to cytokines, as well as human and murine islets. [22] [23] [24] [25] Moreover, the development of diabetes in response to streptozotocin is known to induce the endogenous production of stromal cell-derived factor-1 in b-cells, which, in combination with GLP-1, was recently shown to promote the growth, survival and viability of pancreatic b-cells.
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The observed reduction of a-cell population in streptozotocintreated mice is interesting and highly significant given the importance ascribed to hyperglucagonemia in the metabolic disarray of diabetes. 27 Thus, given the extent of the streptozotocin dose on the b-cell death and ensuing hyperglycemia, the importance of the a-cell/glucagon suppression appears to be of key therapeutic importance in the current study. In addition, it has been recently suggested that under conditions of extreme b-cell loss, viable a-cells have the ability to spontaneously change into b-cells. 28 This could be another factor contributing to decreased a-cell mass and increased b-cell mass following GLUTag cell implantation in diabetic mice. Also notable was the increased GLP-1 content of the small intestines of GLUTag cell-implanted diabetic mice. This possibly reflects inhibition of endogenous intestinal GLP-1 secretion. However, unlike transplantation of insulin-secreting cells, which has been noted to cause disturbances of pancreas and islet structure in rats, 29 no changes of small intestine morphology or L-cell numbers were evident in the current study.
In conclusion, chronic GLP-1 delivery by cell therapy has significant beneficial effects on body weight and metabolic control in SCID diabetic mice, without affecting either parameter in normal controls. The positive effects in diabetes were associated with enhanced insulin secretion and b-cell mass expansion, whereas both a-cell mass and circulating glucagon were suppressed. Although the actions of other less wellcharacterized GLUTag secretions cannot be ruled out, these results represent proof of concept that chronic GLP-1 delivery by cell therapy affords a possible means of improving metabolic control in type 1 as well as type 2 diabetes.
MATERIALS AND METHODS Animals
Adult female SCID mice weighing 15-28 g (Harlan UK Ltd, Shaw's farm, Blackthorn, UK) were maintained under specific pathogen-free conditions in the Biomedical and Behavioural Research Unit (BBRU) at University of Ulster, Coleraine. Mice were housed individually in sterile cages in an air-conditioned room at 22 ± 2 1C with 12 h light and 12 h dark cycle, with standard sterilized rodent maintained pellet diet (Trouw Nutrition, Northwich, Chesire, UK) and sterilized drinking water available ad libitum. Diabetes was induced by intraperitoneal injection of 12 h fasted mice with 150 mg kg À 1 streptozotocin freshly prepared in ice-cold 0.1 M sodium citrate buffer, pH 4.5. Plasma glucose concentrations were measured every 2 days after streptozotocin administration using an Ascencia Contour glucose meter (Bayer Healthcare, Uxbridge, UK). All animal procedures were carried out according to the UK home office regulations (UK Animal Scientific Procedures Act 1986) and 'Principles of laboratory animal care' (NIH Publication no 86-23, revised 1985).
Cell culture and transplantation
GLUTag cells (courtesy of Professor DJ Drucker, Toronto, Canada), originally derived by subcutaneous implantation of glucagon gene-simian virus-40 large T-antigen (GLUTag) fusion tumor cells in nude mice followed by single-cell cloning, 21 were maintained in Dulbecco's modified Eagle's medium containing 5.5 mM glucose and 2 mM L-glutamine, 10% (v/v) fetal bovine serum and antibiotics (penicillin (100 U ml À 1 ), streptomycin (0.1 mg l À 1 ) as described previously. 14 Before transplantation, GLUTag cells were suspended at a density of 50 Â 10 6 cells per ml and 100 ml injected subcutaneously at the subscapular region of normoglycemic or diabetic mice 10 days after streptozotocin using a 25-G needle, carefully avoiding penetration into fat or entry of cell suspension into capsular tissue. Control animals were injected with 100 ml vehicle (warm Dulbecco's modified Eagle's medium without fetal bovine serum and antibiotics). To avert life-threatening diabetes, mice received insulin (15 U per kg body weight bovine insulin, Sigma-Aldrich, Poole, UK) for 7-29 days after streptozotocin treatment as indicated in the Figures. Food intake, water intake and body weight were monitored on a daily basis and plasma glucose once every 3 days.
Glucose tolerance and biological analysis
Glucose tolerance test was carried out at 30 days post cell transplantation. Baseline (0 min) blood glucose reading was determined and after intraperitoneal injection of glucose (18 mmol per kg body weight) at 15, 30, 45, 60 and 90 min. All blood samples were collected immediately in fluoride/heparin microcentrifuge tubes (Sarstedt, Numbrecht, Germany). Blood was immediately centrifuged for 30 s at 13 000 g. The resulting plasma was collected and stored at À 20 1C until analyzed for insulin by radioimmunoassay, 30 or total GLP-1 and glucagon by specific electrochemiluminescent immunoassays using a SECTOR Imager 2400 Chronic GLP-1 cell therapy S Vasu et al (Meso Scale Discovery, Gaithersburg, MD, USA). 31 Tissues extracted with acid ethanol (750 ml ethanol, 235 ml water, 15 ml concentrated HCl) were similarly analyzed for GLP-1.
Immunohistochemistry
At the termination of experiments, resected GLUTag cell masses, pancreas and small intestine were fixed in 4% paraformaldehyde and processed using automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany). Embedded tissues were then sectioned at a 10-mm thickness using microtome (Shandon Finesse 325, Thermo Scientific, Hemel Hempstead, UK). Tissue sections were deparaffinized, rehydrated and probed with primary antibodies: rabbit anti-insulin antibody (1:200; Santa Cruz, Heidelberg, Germany), guinea-pig anti-glucagon antibody (PCA2/4, 1:200; raised in-house) or rabbit anti-GLP-1 antibody (XJIC8, 1:200; raised in-house). 32 For fluorescent immunohistochemistry, sections were incubated with secondary antibody (Alexa Fluor 594 goat anti-guinea pig IgG (1:400) and Alexa Fluor 488 goat anti-rabbit IgG (1:400); both from Invitrogen, Paisley, UK) and mounted using anti-fade mounting medium or aqueous mounting medium (glycerol/phosphate-buffered saline (1:1)). The slides were then viewed under fluorescein isothiocyanate filter (488 nm) or tetramethylrhodamine isothiocyanate filter (594 nm) using a fluorescent microscope (Olympus System Microscope, model BX51; Southend-on-Sea, UK) and photographed using the DP70 camera adapter system. For peroxidase immunohistochemistry, the sections were incubated with ImmPRESS antirabbit Ig (peroxidase) reagent and 3,3 0 -Diaminobenzidine substrate, and counterstained with hematoxylin. Color was developed by rinsing in acid alcohol and tap water. The slides were viewed using Olympus IX51 inverted microscope ( Â 20 magnification) and photographed using the SPOT RT-Ke camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA). Images were analyzed using Cell^F analysis software (Olympus) and islet area together with related parameters were measured using the closed polygon tool. Percentage pancreatic b-cell area was calculated from insulin-positive area/total islet area. Approximately 20-30 islets per mouse were analyzed.
Ki-67and TUNEL immunostaining
For Ki-67 staining, pancreatic sections were incubated in 0.5% Triton X-100 for 20 min. Sections were then incubated with mouse anti-Ki67 antibody (1:500; Sigma-Aldrich), visualized using DAB (Vector Laboratories, Burlingame, CA, USA) and counterstained with methyl green. For TUNEL staining, sections were dewaxed, rehydrated, exposed to 0.5% Triton X-100 and incubated with mouse anti-insulin antibody (1:1000, Sigma-Aldrich) followed by Alexa Fluor 594 goat anti-mouse IgG (Invitrogen). Sections Po0.01 compared with non-diabetic control. ND, not detectable.
Chronic GLP-1 cell therapy S Vasu et al dehydration, sections were mounted and then viewed using an Olympus IX51 inverted microscope, Â 20 magnification and photographed using SPOT RT-Ke camera (Diagnostic Instruments Inc.).
Statistics
Results are expressed as mean±s.e.m. Groups of data were compared using an unpaired Student's t-test in GraphPad PRISM (version 3.0). Differences were considered significant if Po0.05.
